EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE

Post-LOE

emtricitabine and tenofovir disoproxil fumarate

Hetero

ANDAORALTABLET

Approved

Oct 2021

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

3/8 — Basic

EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE (emtricitabine and tenofovir disoproxil fumarate) by Hetero is nucleoside reverse transcriptase inhibitors [moa]. Approved for at-risk adults, adolescents weighing at least 35 kg for pre-exposure prophylaxis (prep) to reduce the risk of sexually acquired hiv-1 infection, combination with other antiretroviral agents for the treatment of hiv-1 infection in adults. First approved in 2021.

Drug data last refreshed 20h ago

Mechanism of Action

Nucleoside Reverse Transcriptase Inhibitors

Pharmacologic Class:

Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor

Indications (3)

at-risk adults adolescents weighing at least 35 kg for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection

Worked on EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE at Hetero? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.